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The recent proposed criteria for Alzheimer’s Disease (AD) have strongly claimed the usefulness of biological and neuroimaging
markers for early identiﬁcation AD. Cerebrospinal ﬂuid (CSF) Tau/Abeta ratio, hippocampal atrophy, posterior cingulate, and
neocortical associative area hypometabolism, or amyloid burden evaluated by PiB compound, held the premises to increase
diagnosticaccuracyinthepreclinicaldiseasestages.Despite manyeﬀortstoidentifysubjectsatriskofdevelopingAD,lessattention
has been paid to presenile AD diagnosis.A few data are already availablein early onset AD, mainlyobtained in cases of monogenic
disorder. In this paper, we discuss the current literature on the role of biological and neuroimaging markers in presenile AD.
1.Introduction
Alzheimer’s Disease (AD) is the most common form of neu-
rodegenerative dementia, with an incidence that increases
with age [1].
Typically, the core clinical features of AD are memory
impairment, related to early tissue damage within hip-
pocampus and medial temporal lobes [2]. However, AD is
rather clinically heterogeneous and there has been increasing
awareness of atypical AD forms, which are characterized
at disease onset by either language deﬁcits, behavioural
disturbances, or visuospatial abnormalities [3–7]. AD may
be termed late-onset AD when the onset of symptoms
is at 65 years or later, and early-onset AD (EOAD) with
symptoms beginning before 65 years of age. The atypical
presentations are more frequent in EOAD than in late-onset
disease. Notwithstanding, the diﬀerential diagnosis between
EOADandpsychiatric disturbances, metabolicdisorders and
even other neurodegenerative dementias associated with an
early disease onset,namely, frontotemporaldementia(FTD),
corticobasal degeneration, and posterior cortical atrophy,
is of particular importance in light of the emergence of
potential disease modifying therapies in the future.
Recent proposed consensus criteria for AD have under-
linedtheroleplayedbybiologicalandneuroimagingmarkers
for disease diagnosis [8]. Accordingly, cerebrospinal ﬂuid
(CSF)Tau/Abeta ratio, hippocampal atrophy as measured by
MRI, posterior-cingulated and neocortical-associative area
hypometabolism as detected by FDG-PET, and amyloid
burdenevaluatedbyPiBcompoundhavebeenclaimedasthe
ﬁngerprints of preclinical AD.
However, in spite of the wide body of literature on
the accuracy of biological and neuroimaging markers in
identifying subjects at risk of developing AD, much less
attention has been devoted to EOAD. Diﬀerent reasons may
be addressed for this: ﬁrst, presenile AD is a rare disorder as
compared to late-onset disease, thus being diﬃcult to collect
a reasonable sample of patients to draw reliable results;
second, in most of cases, investigators, considering EOAD
to be genetically based, give too much attention to genetics
determinants and less attention has been paid to biomarkers.
Theaimofthepresentworkistoreviewtheavailabledata
on the role of biological and neuroimaging tools that might
be helpful in carefully detecting EOAD and to discuss the
need of future clinical trials to deﬁne diagnostic algorithms
for EOAD.2 International Journal of Alzheimer’s Disease
2.GeneticDiagnosis inEarly-Onset
Alzheimer’sDisease
The majority of AD cases are sporadic buta relatively small
numberofcases(25%),presentfamilial aggregation(familial
AD, FAD). FAD is typically associated with EOAD (60% of
EOAD is familial), with 13% appearing to be transmitted as
a pure genetic, autosomal dominant trait [9].
In the last years, mutations in three genes have been
described as the cause of some familial forms of EOAD, and
these cases with known pathogenetic mutations are named
monogenic AD.
Firstly, in 1991, mutations within the “Amyloid Pre-
cursor Protein gene (APP)” on chromosome 21q21.3 were
ﬁrstly reported, and more than 32 pathogenetic mutations
have been described so far (http://www.molgen.ua.ac.be/
ADMutations). APP mutations account for less than 5% of
autosomal dominant EOAD [9]. The APP gene encodes for
a polypeptide of 770 amino acids that may be involved in
nuclear signaling [10]. It has been shown that APP protein
can be processed by at least two separate pathways, one
involves α-secretases cleavage and the other requires sequen-
tial proteolysis by β-a n dγ-secretases to generate Aβ40–43
peptides [11]. Aβ42-43 were considered the more neurotoxic
isoforms and were found increased in the brains of AD
patients [12]. Interestingly, pathogenetic mutations within
APP gene are clustered very close the secretase cleavage sites,
thus exerting a direct eﬀect on APP processing [13].
Families with APP mutations show variable age of onset
ranging from 31 to 60 years and are clinically deﬁned by
EOAD frequently associated with cerebral amyloid angiopa-
thy[14]; some cases have been reported with atypical clinical
presentation at symptom onset, resembling Dementia with
Lewy Bodies or epilepsy [15, 16].
Some years later to the identiﬁcation of APP mutations,
pathogenetic variations within “Presenilin 1gene (PSEN1)”
on chromosome 14q24.3 were identiﬁed as key to disease
pathogenesis. PSEN1 mutations represent the most common
cause of autosomal dominant EOAD (18–50%), and more
than 180 mutations have been identiﬁed [17, 18].
PSEN1 gene encodes a transmembrane protein of 476
amino acids that actsas catalyticfor the γ-secretase complex.
The majority of the known mutations are missense substi-
tutions and show almost complete penetrance by the age 60
years [19].
PSEN1 mutationshave beenassociated withawide range
in age of onset, ranging from very early-onset (before age 30
years) to cases with onset later than 80 years old [18, 20, 21].
Ithas beendemonstrated that carrying PSEN1 mutationsisa
negative prognostic factoron survival as comparedto PSEN2
mutations or sporadic late-onset AD [22].
Phenotypic heterogeneity is common in patients with
PSEN1 mutations. Although the majority of known PSEN1
genetic variations are associated with classical EOAD, several
cases have been reported to have atypical features, namely,
myoclonus and seizures [23, 24], extrapyramidal signs [23],
behavioural and psychiatric symptoms, early aphasia [23,
25],visual agnosia [26],cerebellarataxia [27,28],and spastic
paraparesis [23, 29].
Conversely, the third gene responsible for autosomal
dominant-inherited disorder, that is, “Presenilin 2 (PSEN2)”
maps on chromosome 1q31-42, and it does not represent
a common cause of EOAD. Only 14 pathogenic mutations
have been described so far [30, 31]. PSEN2 gene encodes for
a transmembrane protein of 448amino acids that, as PSEN1,
plays a role as a catalytic core of the γ-secretase complex.
The clinical phenotypeassociated with PSEN2mutations
is still not clearly deﬁned, as a few cases are available. Up
to now, 7 out of 14 mutations are likely to be pathogenetic
[22]and theyhave beenassociated with ADwith age at onset
ranging from 39 to 75 years.
Some mutations were associated with atypical or dis-
tinctive clinical features: A85V mutation was described in
a family with dementia and parkinsonism and with a
clinical diagnosis of Dementia with Lewy Bodies in one
member; T122R mutation was reported in subjects with
frontotemporal dementia-like phenotype [32], whilst N141I
mutationwasassociated withseizuresin32%ofcarriers[30–
33]. Twelve patients carrying N141I mutation underwent
neuropsychological testing and memory loss and impair-
ment in verbal ﬂuency, spatial perception deﬁcits, acalculia,
and executive dysfunctions were reported.
I ns u m m a r y ,E O A Da c c o u n t sf o r1 – 5 %o fA Dc a s e s
[34]. It has been shown that mutations within APP, PSEN1,
or PSEN2 (see Table 1) can explain up to 71% of the
autosomal dominant transmission pattern in FEOAD [35].
The screeningfor knownpathogeneticmutations,in patients
with appropriate phenotype and familial EOAD with auto-
somal dominanttransmission pattern, should be considered
useful in clinical practice, but it should be accompanied
by neurogenetic counselling and undertaken only after full
consent and by specialist centres.
It is however true that the wide spectrum of clinical
symptoms of monogenic AD, beyond memory disturbances,
claims for the need of biological and neuroimaging markers
thatcanbeofhelpinsuggesting DNAsequencing.Moreover,
most of EOAD cases are not explained by known Mendelian
mutations, and also in these cases there is a need for
biomarkers for an accurate diagnosis.
3.Biological and NeuroimagingMarkersin
Detecting Early-Onset Alzheimer’s Disease
The recent publishedcriteria forADhave strongly supported
the usefulness of biological and neuroimaging markers for
improving diagnostic accuracy in preclinical stages [9].
It is well established that reduced CSF Abeta42 levels
and increased CSF Tau levels are the signature of AD. In the
same way, hypometabolism of posterior cingulate cortex and
temporoparietal regions and hippocampal atrophy are the
neuroimaging hallmark of the disease [8].
However, the usefulness of these markers in EOAD has
been poorly tested, and no reliable large sample size studies
in EOAD patients compared to other neurodegenerative
dementias are available yet.International Journal of Alzheimer’s Disease 3
Table 1: Monogenic forms of Early-Onset Alzheimer’s Disease (EOAD).
Gene Locus N◦ mutations Clinical presentation
APP 21q21.3 32 O n s e tf r o m3 1t o6 0y e a r s .
EOAD frequently associated with cerebral amyloid angiopathy
PSEN1 14q24.3 >180
Onset before age 30 years to cases with onset later than 80 years
old.
ClassicalEOAD, several cases with atypical features: myoclonus
and seizures, extrapyramidal signs,behavioural and psychiatric
symptoms, early aphasia,visual agnosia,cerebellar ataxia, and
spastic paraparesis.
PSEN2 1q31-42 14 O n s e tf r o m3 9t o7 5y e a r s .
Atypical features: dementia and parkinsonism, frontotemporal
dementia-like phenotype, seizures.
APP: amyloid precursor protein; PSEN: presenilin.
3.1. Cerebrospinal Fluid for EOAD Diagnosis. Sporadic and
FADsharecommonpathogeneticmechanisms, asneurotoxic
forms of amyloid appear to be elevated in both cases. Thus,
it can be hypothesised that CSF analysis might be of help
in EOAD as well. The current ﬁndings on CSF markers are
based on case reports and small samples of EOAD mutation
carriers, namely with PSEN1 genetic variations.
To date, more than 180 mutations in PSEN1 have been
detected (http://www.molgen.ua.ac.be/ADMutations). It has
been reported that pathogenetic PSEN1 genetic variations
lead to signiﬁcant increases in plasma Abeta42 levels and
massive amyloid deposition in the brain [36, 37]. A role of
PSEN1 mutations in Tau pathology has also been suggested
by the ﬁnding of tau hyperphosphorylation in PSEN1
transgenic mice [38].
In a recent work, it has been demonstrated that in a
case of presenile dementia, spastic paraparesis, and frontal
executivefunction impairment, CSFanalysis facilitated DNA
diagnosis. Increased CSF total Tau levels and decreased
CSF Abeta42 dosage distinguished this familial EOAD from
Creutzfeldt Jacob disease and frontotemporal dementia
[39]. A causative PSEN1 L424R mutation was subsequently
identiﬁed [39].
In the same view, a CSF pattern resembling that found in
late-onset AD pointed towards genetic analysis in a case of
PSEN1 Q223R mutation [40]; the patient presented familial
early-onset dementia at the age of 35 years along with spastic
paraplegia and behavioural symptoms.
Interestingly, CSF biomarkers have been demonstrated
useful not only in distinguishing EOAD from other neu-
rodegenerative dementias, but also in predicting AD-related
mutations in cases with clinical and skin biopsy features
suggestivefor storagedisease [41].A patient with progressive
cognitive decline associated with delusions, myoclonus,
and seizure and with no family history for dementia was
diagnosed as cereidolipofuscinosis; once CSF analysis was
carried out and AD-like pattern reported, de-novo PSEN1
P117L mutation was identiﬁed and the diagnosis of EOAD
made.
Up to now, no extensive data on CSF analysis in PSEN2
carriers have been performed, as rare causes of EOAD.
However, in a case of PSEN2 N141I mutation, the CSF
pattern was comparable to sporadic AD.
3.2. Functional Neuroimaging forEOAD Diagnosis. If in both
EOAD and in sporadic late-onset AD, CSF data are almost
comparable, diﬀerent ﬁndings may be obtained when neu-
roimaging markers are considered.
Little is known about the usefulness of neuroimaging
in the diﬀerential diagnosis with other neurodegenerative
dementias. In fact, it has been widely demonstrated that the
cognitive pattern of EOAD is diﬀerent from late-onset AD,
in the former the neocortical functions are more aﬀected.
Accordingly, EOAD and late-onset AD diﬀer in their typical
topographic patterns of brain atrophy [42].
Indeed, in monogenic EOAD cases, neuroimaging
reports usually show the pattern of sporadic AD, involving
temporoparietalareas,butextrabrainregionsnotcommonly
observed in typical AD cases are described. It has been
demonstrated that patients with EOAD due to PSEN1
mutations (i.e., His163Tyr) showed greater hypometabolism
not only in the posterior cingulate but in frontal cortex as
well [43] and thalamic hypometabolism was found in EOAD
case carrying APP Val717Ile mutation [44].
Some authors evaluated the role of PiB-compound,
a Positron Emission Tomography (PET) tracer binding
amyloid, in early diagnosis of EOAD. In a PSEN1 His163Tyr
case, PiB binding was comparable to sporadic AD, but
slightly higher striatal levels were detected [43]. The same
ﬁndings were obtained evaluating ten PSEN1m u t a t i o n
carriers, with intense and focal PiB retention in the striatum
[45]. Moreover, in most PSEN1 mutation carriers, there also
were increases in PiB retention compared to controls in
cortical brain areas, but these increases were not as great as
those observed in sporadic AD subjects [45].
Another interesting work aimed at evaluating PiB distri-
bution in EOAD in seven PSEN1 mutation carriers and one
APP mutation carrier [46]: the authors demonstrated that
all mutation carriers had high PiB retention in the striatum,
with some also having cortical PiB retention in ventrofrontal
and posterior cingulate/precuneus areas. The striatal pattern4 International Journal of Alzheimer’s Disease
of PiB retention was similar in the PSEN1 and APP mutation
carriers [46].
These studies suggested that the pattern of Abeta depo-
sition in FAD diﬀers from that in sporadic AD, with higher
striatal and somewhat lower cortical PiB retention in FAD.
3.3. Structural Neuroimaging for EOAD Diagnosis. Studies
on structural neuroimaging have strongly supported the
usefulness of hippocampal measures in early diagnosis of
AD. From pathological and MRI studies, the hippocampus
is known to be severely aﬀected in established AD [47, 48].
Hippocampal volumes have consistently been shown to be
reduced by as much as 40% in patients with clinically
diagnosed AD, the extent of atrophy correlating with disease
severity [49]. Hippocampal atrophy has been introduced in
current proposed criteria for preclinical diagnosis of AD
[8, 50].
In EOAD, the available data seem to suggest that evaluat-
ing hippocampal atrophy may be of help.
In a case of PSEN1 S170F mutation, cortical brain
atrophy, particularly within hippocampus, frontal and tem-
poral cortex, was reported [51]. However, as demonstrated,
patients with EOAD showed greater neocortical atrophy at
the temporoparietal junction, while the patients with lateon-
set AD showed greater hippocampal atrophy [52]. Taken
together, these results argue that hippocampus evaluation is
a signature in EOAD as in late-onset disease.
3.4. Biological and Neuroimaging Markers in Presymptomatic
Subjects with EOAD. A few studies have estimated the
importance of biological and neuroimaging markers in
presymptomatic subjects with known mutations. As, in
these, casesgenetic testing is exhaustive, the role of markers
has not been fully elucidated. Indeed, the assessment of
biological and neuroimaging markers in presymptomatic
subjects carrying pathogenetic mutations might be of help
in deﬁning the time of conversion. Diagnosis in subjects
carrying pathogenetic mutations represents a very delicate
aspect with even profound ethical implications that should
be treated cautiously and only in the frame of controlled
research protocols.
The usefulness of CSF biomarkers has been tested on
six presymptomatic subjects with pathogenetic mutations in
the PSEN1 gene [53], and CSF Abeta42 levels were found to
be signiﬁcantly lower than age-matched control group. No
other data are still available.
Studies in presymptomatic carriers employing imaging
techniques like PET and single photon emission computed
tomography have revealed regional abnormalities in cerebral
glucose metabolism [54] and brain blood-ﬂow [55]p r i o r
to the development of clinically signiﬁcant impairment.
Likewise,very early pathologicalchanges in termsofamyloid
deposition have been shown in a study of young presymp-
tomatic PSEN1 carriers by using 11C-PiB-PET [45]. A recent
study carried out in presymptomatic and mildly aﬀected
PSNE1 carriers revealed signiﬁcantly greater thalamic reten-
tion than sporadic AD [56]. Moreover, a few individuals
with PSNE1 mutations showed increased cerebellar 11C-PiB
retention suggesting that this region may not be as suitable
as a reference region in FAD [56].
Finally, volumetric measurement of hippocampus show-
ed asymmetrical atrophy in seven presymptomatic APP
Val717Ile carriers [52].
4.Conclusions
Af e we ﬀorts have been addressed to elucidate the usefulness
of biological and neuroimaging markers in EOAD. Studies
involving larger numbers of individual are required in order
to determine whether and which marker abnormalities are
consistently detected at early disease stage in young onset
d e m e n t i a .U pt on o w ,n oc l e a r - c u tc o n c l u s i o n sm i g h tb e
drawn.
Preliminary datasuggest thatCSFmarkers, such as Abeta
and Tau levels, may be considered as a helpful tool in the
diagnosis of EOAD, as the reported changes are comparable
to those detected in sporadic late-onset AD. Hippocampal
measurement seems to be early aﬀected in EOAD, thus to be
considered in diagnostic workup. Conversely, more data on
functional abnormalities in EOAD are required, as peculiar
pattern of hypometabolism/amyloid accumulation occurs
in the available EOAD cases associated with monogenic
mutations.
The assessment of biomarkers in EOAD should be rec-
ommended in order to increase diagnostic accuracy in those
cases with atypical presentation and/or familial aggregation
of the disease. Biological and neuroimaging markers may be
of help to suggest DNAsequencing of known causative genes
or to support diagnosis of EOADin those cases without APP,
PSEN1, and PSEN2 mutations.
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